drugset / Trial / NCT06005714

Effect of Pharmacokinetics in Healthy Chinese Subjects

NCT06005714

Phase 1 Completed 36 enrolled Shanghai Vinnerna Biosciences Co., Ltd.
Non-randomizedCrossoverOpen-labelOther

Summary

This study is a single-center, open label, self-controlled phase I clinical study, to evaluate the effects of clarithromycin or cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets in healthy Chinese subjects.

Timeline

Start
2023-08-15
Primary completion
2023-10-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule
Subject Cyclosporine Peptide
Subject REMIDEVIR Small molecule

Indications

No indication recorded.